In 2012, the National Institute of Health (NIH) estimated that around 23.5 million Americans have an autoimmune illness. Furthermore, the Department of Health and Human Services revealed in 2017 that autoimmune disease (AID) is placed #1 among the top 10 health topics. Autoimmune disease has a significant impact on one's health, and it can result in a variety of difficulties in numerous parts of the body, including the heart, brain, kidneys, glands, and nerves. Autoimmune disease is becoming more common due to genetic and environmental variables such as dietary components, toxic chemicals, and infections. Irritable bowel disease (IBD), rheumatoid arthritis (RA), multiple sclerosis (MS), celiac disease (CD), hepatitis, autoimmune thyroiditis (AT), systemic lupus erythematosus (SLE), and type 1 diabetes (IDDM) are examples of autoimmune disorders.
The expansion of the autoimmune disease treatment market is projected to be aided by advanced approaches for the treatment of AIDS.
The Autoimmune Disease Treatment Market is projected to benefit from advancements in AID treatment. In 2016, researchers at the Perelman School of Medicine discovered a strategy to target a specific fraction of antibodies that are responsible for the activation of the autoimmune illness pemphigus Vulgaris (PV). The researchers developed chimeric autoantibody receptor treatment (CAART), which can be utilized to treat this disease without affecting the immune system's normal function.
The autoimmune disease treatment market is predicted to develop due to rising awareness of autoimmune disorders and rising demand for therapeutic techniques.
Governments and biopharmaceutical companies are investing in research & development to discover new treatments and therapies for the treatment of autoimmune diseases, which is projected to be a major driving factor for the market's growth in the near future.
The autoimmune disease treatment market is predicted to develop due to rising awareness of autoimmune disorders and rising demand for therapeutic techniques.
Governments and biopharmaceutical companies are investing in research & development to discover new treatments and therapies for the treatment of autoimmune diseases, which is projected to be a major driving factor for the market's growth in the near future.
Johnson & Johnson, Abbott Laboratories, F. Hoffmann-La Roche Ltd., Active Biotech, GlaxoSmithKline plc, Eli Lilly and Company, AutoImmune Inc., Pfizer, Inc., AstraZeneca plc, Lupin Limited, 4SC AG, Amgen, Inc., and Bristol-Myers Squibb are some of the major players in the global autoimmune disease treatment market.
0 Comments